Ventolin
GSK’s low carbon inhaler, Ventolin, progresses to phase 3 trialsÂ
November 21, 2023Medical Communications Asthma & COPD, GSK, Ventolin, asthma, carbon-neutral
GSK has announced that in 2024 it intends to start phase 3 trials of a low carbon version of its …
GSK hit by recall of 600,000 inhalers
April 5, 2017Manufacturing and Production, Research and Development FDA, GSK, Ventolin
The FDA has released that GSK would be voluntarily recalling close to 600,000 of its Ventolin asthma inhalers across the …
Latest content
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
EnteroBiotix appoints former GSK Chief Medical Officer to board
November 3, 2026
